Skip to main content
. Author manuscript; available in PMC: 2012 Apr 12.
Published in final edited form as: Angew Chem Int Ed Engl. 2011 Nov 24;51(2):450–454. doi: 10.1002/anie.201105670

Scheme 1.

Scheme 1

a) Structure of the ADA-functionalized magnetofluorescent nanoparticles (ADA–MFNPs) and CD-modified antibodies (CD–Abs). b) Schematic depiction of the supramolecular labeling strategy. CD–Abs against the biomarker of interest were initially targeted to cells and then used as scaffolds for coupling ADA–MFNPs in live cells by host–guest complexation between CD and ADA.